Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Urothelial Carcinoma: Clinical Diagnosis and Treatment: Part II
share announcement

Urothelial Carcinoma: Clinical Diagnosis and Treatment: Part II

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: 8 October 2024 | Viewed by 4379

Special Issue Editor

Prof. Dr. Massimiliano Creta

E-Mail Website
Guest Editor
Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy
Interests: bladder cancer; radical cystectomty; radical nephroureterectomy; transurethral resection of bladder tumor; upper urinary tract urothelian carcinoma
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

It is my pleasure to invite you to contribute to the Special Issue entitled "Urothelial Carcinoma: Clinical Diagnosis and Treatment: Part II". This is a new volume and we previously published 11 papers in the first volume. For more details, please visit:
https://www.mdpi.com/journal/jcm/special_issues/Clinical_Urothelial_Carcinoma

Urothelial carcinoma (UC) represents the most common type of epithelial tumor diagnosed in Europe, North America, South America, and Asia. Although around 70–75% of newly diagnosed UC manifests as non-muscle invasive bladder cancer, it can also involve the renal pelvis, ureter, and urethra. UC is a multifocal process, with tobacco smoking being the most relevant risk factor in developed countries. Patients with UC of the upper urinary tract have a 30% to 50% chance of developing cancer of the bladder, while patients with bladder cancer have a 2% to 3% chance of developing cancer of the upper urinary tract. Currently, UC represents a clinical and social challenge because of its incidence, post-treatment recurrence rate, and prognosis. In recent years, the poor diagnostic accuracy of the available diagnostic tools such as urine cytology, white cystoscopy, and conventional imaging modalities have emphasized the urgent need for advancement in clinical guidance for UC. Moreover, novel treatment approaches, both medical and surgical, have significantly impacted the management of these patients. At the same time, the quality of life of these patients has gained growing interest. This Special Issue presents up-to-date summaries related to the diagnosis, prognostic assessment, and management of UC.

Prof. Dr. Massimiliano Creta
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • bladder cancer
  • radical cystectomy
  • radical nephroureterectomy
  • transurethral resection of bladder tumor
  • upper urinary tract urothelian carcinoma

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

10 pages, 783 KiB  
Article
Stratifying the Risk of Disease Progression among Surgically Treated Muscle-Invasive Bladder Cancer Eligible for Adjuvant Nivolumab
by Rocco Simone Flammia, Gabriele Tuderti, Eugenio Bologna, Antonio Minore, Flavia Proietti, Leslie Claire Licari, Riccardo Mastroianni, Alfredo Maria Bove, Umberto Anceschi, Aldo Brassetti, Maria Consiglia Ferriero, Salvatore Guaglianone, Giuseppe Chiacchio, Fabio Calabrò, Costantino Leonardo and Giuseppe Simone
J. Clin. Med. 2024, 13(18), 5466; https://doi.org/10.3390/jcm13185466 - 14 Sep 2024
Viewed by 479
Abstract
Background: Check-Mate 274 has demonstrated the disease-free survival (DFS) benefit of adjuvant nivolumab in surgically treated muscle-invasive bladder cancer (MIBC). Since immunotherapy represents an expensive treatment with potential side effects, a better understanding of patient-specific risks of disease progression might be useful for [...] Read more.
Background: Check-Mate 274 has demonstrated the disease-free survival (DFS) benefit of adjuvant nivolumab in surgically treated muscle-invasive bladder cancer (MIBC). Since immunotherapy represents an expensive treatment with potential side effects, a better understanding of patient-specific risks of disease progression might be useful for clinicians when weighing the indication for adjuvant nivolumab. Objective: To identify the criteria for risk stratification of disease progression among MIBC patients eligible for adjuvant nivolumab. Materials and methods: A single-institution, prospectively maintained database was queried to identify patients eligible for adjuvant nivolumab according to Check-Mate 274 criteria. To account for immortal bias, patients who died or were lost to follow-up within 3 months of undergoing a radical cystectomy (RC) were excluded. Kaplan–Meier and Cox regression analyses addressed DFS, defined as the time frame from diagnosis to the first documented recurrence or death from any cause, whichever occurred first. Regression tree analysis was implemented to identify criteria for risk stratification. Results: Between 2011 and 2022, 304 patients were identified, with a median follow-up of 50 (IQR 24–72) months. After multivariable adjustment, including NAC as a potential confounder, higher CCI (HR 1.56, 95%CI 1.10–2.21, p = 0.013), T stage (HR 2.06, 95%CI 1.01–4.17, p = 0.046), N stage (HR 1.73, 95%CI 1.26–2.38, p = 0.001) and presence of LVI (HR 1.52, 95%CI 1.07–2.15, p = 0.019) increased the risk of disease recurrence or death. Finally, a two-tier classification was developed. Here, five-year DFS rates were 56.1% vs. 18.1 for low vs. high risk (HR: 2.54, 95%CI 1.79–3.62, p < 0.001). Conclusions: The current risk classification, if externally validated on larger samples, may be useful when weighing the risk and benefit of adjuvant nivolumab treatment and making patients more aware about their disease and about the need for additional treatment after RC. Full article
(This article belongs to the Special Issue Urothelial Carcinoma: Clinical Diagnosis and Treatment: Part II)
►▼ Show Figures

Figure 1

13 pages, 1075 KiB  
Article
Prognostic Value of Postneoadjuvant Chemotherapy Neutrophil-to-Lymphocyte Ratio in Patients undergoing Radical Cystectomy
by Krystian Kaczmarek, Bartosz Małkiewicz, Adam Gurwin, Wiktor Mateusz Krawczyk, Karolina Skonieczna-Żydecka and Artur Lemiński
J. Clin. Med. 2024, 13(7), 1953; https://doi.org/10.3390/jcm13071953 - 28 Mar 2024
Viewed by 860
Abstract
Background: Neutrophil-to-lymphocyte ratio (NLR), a widely assessed biomarker in most common diseases, is typically evaluated before treatment initiation. However, data on NLR in the post-treatment setting is limited. Therefore, we assessed the NLR calculated after neoadjuvant chemotherapy (NAC) initiation in patients with bladder [...] Read more.
Background: Neutrophil-to-lymphocyte ratio (NLR), a widely assessed biomarker in most common diseases, is typically evaluated before treatment initiation. However, data on NLR in the post-treatment setting is limited. Therefore, we assessed the NLR calculated after neoadjuvant chemotherapy (NAC) initiation in patients with bladder cancer (BC). We hypothesised that changes in blood cells after NAC could be a marker of tumour response and long-term survival. Materials and Methods: Our study included 214 patients who underwent NAC followed by radical cystectomy (RC) in two urological departments, wherein post-NAC NLR was used to categorize patients into the low (NLR ≤ 1.75) and high (NLR > 1.75) groups. Results: Logistic regression analysis indicated that a post-NAC NLR ≥ 1.75 is a good biomarker for pathologic response (odds ratio (OR), 0.045; p <0.001), emphasizing its ability to predict patient survival. The HRs for overall survival and cancer-specific survival were 2.387 (p = 0.048) and 2.342 (p < 0.001), respectively. Conclusions: We believe that post-NAC NLR can be used for patient stratification after NAC. Consequently, the post-NAC NLR may serve as a guide for the decision-making process regarding RC versus bladder-preserving strategies. Full article
(This article belongs to the Special Issue Urothelial Carcinoma: Clinical Diagnosis and Treatment: Part II)
►▼ Show Figures

Figure 1

Review

Jump to: Research

11 pages, 588 KiB  
Review
Incidence, Timing, and Pattern of Atypical Recurrence after Minimally Invasive Surgery for Urothelial Carcinoma
by Gabriele Bignante, Celeste Manfredi, Francesco Lasorsa, Angelo Orsini, Leslie Claire Licari, Eugenio Bologna, Daniel F. Roadman, Daniele Amparore, Giuseppe Lucarelli, Luigi Schips, Cristian Fiori, Francesco Porpiglia and Riccardo Autorino
J. Clin. Med. 2024, 13(12), 3537; https://doi.org/10.3390/jcm13123537 - 17 Jun 2024
Viewed by 1044
Abstract
The management of urothelial carcinoma has evolved with the introduction of minimally invasive techniques such as laparoscopic or robotic procedures, challenging the traditional approach of open surgery, and giving rise to atypical recurrences (ARs). ARs include port-site metastasis and peritoneal carcinomatosis, yet discrepancies [...] Read more.
The management of urothelial carcinoma has evolved with the introduction of minimally invasive techniques such as laparoscopic or robotic procedures, challenging the traditional approach of open surgery, and giving rise to atypical recurrences (ARs). ARs include port-site metastasis and peritoneal carcinomatosis, yet discrepancies persist among authors regarding their precise classification. Incidence rates of ARs vary widely across studies, ranging from less than 1% to over 10% in both muscle-invasive bladder cancer (MIBC) and upper tract urothelial tumor (UTUC). Peritoneal metastases predominate as the most common ARs in patients with MIBC, while retroperitoneal metastases are prevalent in those with UTUC due to differing surgical approaches. The timing of AR presentation and survival outcomes closely mirror those of conventional recurrences, with which they are frequently associated. Pneumoperitoneum has progressively been regarded less as the cause of ARs, while surgical-related risk factors have gained prominence. Current major surgical-related causes include tumor spillage and urinary tract violation during surgery, avoidance of endo bag use for specimen extraction, and low surgical experience. Factors such as tumor stage, histological variants, and lympho-vascular invasion correlate with the risk of ARs, suggesting a close association with tumor biology. Further studies are required to better understand the incidence, risk factors, characteristics, and outcomes of ARs. Full article
(This article belongs to the Special Issue Urothelial Carcinoma: Clinical Diagnosis and Treatment: Part II)
►▼ Show Figures

Figure 1

10 pages, 230 KiB  
Review
Plasma-Derived Cell-Free DNA as a Biomarker for Early Detection, Prognostication, and Personalized Treatment of Urothelial Carcinoma
by Sophia Bhalla, Rachel Passarelli, Antara Biswas, Subhajyoti De and Saum Ghodoussipour
J. Clin. Med. 2024, 13(7), 2057; https://doi.org/10.3390/jcm13072057 - 2 Apr 2024
Cited by 3 | Viewed by 1520
Abstract
Bladder cancer (BC) is one of the most common malignancies in the United States, with over 80,000 new cases and 16,000 deaths each year. Urothelial carcinoma (UC) is the most common histology and accounts for 90% of cases. BC management is complicated by [...] Read more.
Bladder cancer (BC) is one of the most common malignancies in the United States, with over 80,000 new cases and 16,000 deaths each year. Urothelial carcinoma (UC) is the most common histology and accounts for 90% of cases. BC management is complicated by recurrence rates of over 50% in both muscle-invasive and non-muscle-invasive bladder cancer. As such, the American Urological Association (AUA) recommends that patients undergo close surveillance during and after treatment. This surveillance is in the form of cystoscopy or imaging tests, which can be invasive and costly tests. Considering this, there have been recent pushes to find complements to bladder cancer surveillance. Cell-free DNA (CfDNA), or DNA released from dying cells, and circulating tumor DNA (ctDNA), or mutated DNA released from tumor cells, can be analyzed to detect and characterize the molecular characteristics of tumors. Research has shown promising results for ctDNA use in the BC care realm. A PubMed literature review was performed finding studies discussing cfDNA and ctDNA in BC detection, prognostication, and monitoring for recurrence. Keywords used included bladder cancer, cell-free DNA, circulating tumor DNA, urothelial carcinoma, and liquid biopsy. Studies show that ctDNA can serve as prognostic indicators of both early- and late-stage BC, aid in risk stratification prior to major surgery, assist in detection of disease progression and metastatic relapse, and can assess patients who may respond to immunotherapy. The benefit of ctDNA is not confined to BC, as studies have also suggested its promise as a biomarker for neoadjuvant chemotherapy in upper-tract UC. However, there are some limitations to ctDNA that require improvements in ctDNA-specific detection methods and BC-specific mutations before widespread utilization can be achieved. Further prospective, randomized trials are needed to elucidate the true potential ctDNA has in advancements in BC care. Full article
(This article belongs to the Special Issue Urothelial Carcinoma: Clinical Diagnosis and Treatment: Part II)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop